Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2006

View Archived Issues

Janssen claims new anxiolytics in patent literature

Anthrax vaccine rPA-102 well tolerated, induces antibody responses in humans

Bicifadine well tolerated, improves low back pain in clinical studies

Trial data reveal efficacy and safety of extended-release paliperidone ER in schizophrenia

Recent patents impart new therapeutic agents for cancer

AEE-788 effective in an animal model of thyroid cancer

Phase II data on combretastatin A-4 phosphate in ATC warrants future trials

MerLion completes merger with Combinature Biopharm and Athelas

Medarex and GenPat77 to develop antibody products for autoimmune diseases

Auriga and Degussa to develop corticosteroid formulation for GI diseases

NIH to study prime-boost approach in HIV

Citalopram prevents depression in patients undergoing treatment for head and neck cancer

Once-daily dosing of oral methylnaltrexone studied in phase II trial

GammaCan and Life Therapeutics sign term sheet for VitiGam collaboration

Diamyd shows efficacy in phase II type 1 diabetes study

Innovive licenses patent rights to novel doxorubicin prodrug

Further positive phase II findings for Trinam

Phase III results for telavancin in cSSSI

Fresenius Kabi and Sandoz to develop HESylated biopharmaceutical

Acthar Gel sNDA in infantile spasms accepted for review

CE Mark for Repel-CV to reduce adhesions following cardiac surgery

Keppra receives FDA approval for juvenile myoclonic epilepsy

Garenoxacin submission withdrawn in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...